BFC Planning’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.6K Buy
351
+13
+4% +$704 ﹤0.01% 2046
2026
Q2
$18.6K Sell
338
-3
-0.9% -$123 ﹤0.01% 2045
2026
Q1
$11.3K Sell
341
-4
-1% -$119 ﹤0.01% 1989
2025
Q4
$10.3K Hold
345
– – ﹤0.01% 2072
2025
Q3
$12.5K Sell
345
-216
-39% -$7.12K ﹤0.01% 1803
2025
Q2
$20.2K Sell
561
-29
-5% -$1.08K ﹤0.01% 1496
2025
Q1
$23.3K Buy
590
+34
+6% +$1.14K ﹤0.01% 1401
2024
Q4
$16.7K Sell
556
-7
-1% -$201 ﹤0.01% 1539
2024
Q3
$13.2K Buy
+563
New +$12.3K ﹤0.01% 1627

Other funds holding TGTX

BFC Planning's TGTX Position: Q3 2026 in Review

BFC Planning increased its TG Therapeutics (TGTX) stake by 3.8% in Q3 2026, buying an estimated $704 and bringing the position to 351 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2046.

BFC Planning first reported a position in TGTX in Q3 2024 and has held it in 9 quarters since. The position peaked at $23.3K in Q1 2025. 376 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • BFC Planning held 351 shares of TG Therapeutics worth $19.6K as of Q3 2026.
  • BFC Planning bought 13 TG Therapeutics shares in Q3 2026, an estimated $704.
  • TG Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2046 holding.
  • BFC Planning first reported a position in TG Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's TG Therapeutics position peaked at $23.3K in Q1 2025.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.